Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 180

Pure Storage IPO raises $425m in a flash

The Samsung-backed flash storage technology provider will float at the middle of the IPO's range, and could potentially raise up to $489m.

Oct 7, 2015

Corporates take a hit as Mirna downprices IPO

The Pfizer, Baxter and Celgene-backed oncology company will raise $43.7m from an initial public offering where the share price was effectively halved in the space of two weeks.

Oct 2, 2015

MyoKardia jumpstarts $86m IPO

The cardiovascular-focused pharmaceutical company has raised $94m in equity from investors including strategic partner Sanofi.

Sep 30, 2015

CytomX goes on the IPO attack

Pfizer and Bristol-Myers Squibb will buy a combined $15m of stock in the immuno-oncology drug developer through the offering.

Sep 29, 2015

Pure Storage targets $450m in IPO

The flash storage company, backed by Samsung, has set the range for its initial public offering at $16 to $18 per share, expecting to raise up to $450m.

Sep 25, 2015

Deezer composes IPO plans

ProSiebenSat.1 and Access Industries-backed music streaming service Deezer is set to float on the Paris stock exchange by the end of the year.

Sep 23, 2015

Nabriva prices IPO at $92.3m

Novartis-backed Nabriva has floated on Nasdaq, raising the amount of proceeds it expected when it filed in June 2015.

Sep 21, 2015

RegenXBio prices IPO at $140m

GlaxoSmithKline-backed RegenXBio filed for its initial public offering last month when it expected to raise up to $100m.

Sep 18, 2015

AnaptysBio to adapt to public markets

The Novo-backed biotechnology company has filed for an $86.3m initial public offering, after raising $89m in funding since 2005.

Sep 11, 2015

CytomX marks the spot for $100m IPO

The cancer treatment developer has raised $165m in venture capital from investors including pharmaceutical companies Roche and Pfizer.

Sep 2, 2015
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here